.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AH01_Sirolimus.Sirolimus .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AH01_Sirolimus.Sirolimus| name: | Sirolimus |
| ATC code: | L04AH01 | route: | oral |
| n-compartments | 2 |
Sirolimus is an immunosuppressive drug primarily used to prevent rejection in organ transplantation, particularly kidney transplants. It is an mTOR inhibitor and also has antiproliferative and antifungal properties. It is approved and widely used today.
Reported pharmacokinetics in healthy adult volunteers following single oral dose administration.
Zhang, Y, et al., & Li, X (2021). Population pharmacokinetics of sirolimus in Chinese adult liver transplant recipients: a retrospective study. Xenobiotica; the fate of foreign compounds in biological systems 51(12) 1408–1415. DOI:10.1080/00498254.2022.2025628 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34983304
Wang, D, et al., & Li, Z (2019). Population pharmacokinetics of sirolimus in pediatric patients with kaposiform hemangioendothelioma: A retrospective study. Oncology letters 18(3) 2412–2419. DOI:10.3892/ol.2019.10562 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31452734
Li, S, et al., & Wang, Y (2022). Population Pharmacokinetic Analysis and Dosing Optimization of Sirolimus in Children With Tuberous Sclerosis Complex. Journal of clinical pharmacology 62(8) 948–959. DOI:10.1002/jcph.2033 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35094415